Differential MS analysis of blood samples from diseased and control subjects is increasingly being employed in the hunt for biomarkers that can detect disease at an early stage. For diagnostic tests, in particular for population screening, robust protocols are required that can offer high-throughput analysis, ideally at high mass spectrometric sensitivity. To achieve this, blood samples need to be collected, prepared and analyzed in a standardized manner that minimizes potential bias. Simple purification methods combined with MALDI MS profiling have so far been championed for providing the best approach.
Introduction
The ultimate goal of biomarker research is to establish straightforward, cost-effective, minimally invasive clinical tests with high sensitivity and specificity for early disease detection. Profiling blood and blood-derived products based on mass spectrometry (MS) is becoming a powerful tool to mine the physiologically informative molecules contained in this biofluid [1] [2] [3] . By its nature and availability, blood has the potential to be an ideal medium for elucidating the current state of health. During the last few years many studies, using matrixassisted laser desorption/ionization (MALDI) time-of-flight (TOF) MS coupled with bioinformatics tools, have been reported as being capable of distinguishing between the polypeptide patterns of healthy individuals and patients diagnosed with various diseases 1, [4] [5] [6] .
However, none of the biomarkers identified in these studies have so far been progressed towards their clinical use 7, 8 .
One of the major obstacles for the direct discovery of new biomarkers in blood is due to its complexity, which includes the presence of salts, lipids, and other biological matrix compounds and the high dynamic range of proteins, making it extremely difficult to detect and analyze disease-specific biomarkers by MS. For example, when untreated plasma or serum is analyzed on a standard MALDI target plate, it does not produce any useful spectra.
Thus, to overcome these obstacles there is an obvious need for improved methods to facilitate MALDI MS analysis of blood without losing its diagnostic power. Any such method needs to be employable across many different laboratories and to incorporate high standards and quality control throughout the entire analytical workflow including sample collection, preparation, MS analysis, and data processing and mining [9] [10] [11] .
As a consequence, detailed studies have been reported with the aim of standardizing protocols and reducing systematic biases. Indeed, it has been shown that many non-4 biological variations can be introduced during blood sample collection, preparation, and storage, adding to possible deficiencies in study design and inappropriate data analysis approaches 3, [12] [13] [14] . Some of the resulting standardized protocols are now used with more confidence in discovering and validating new biomarkers with the hope of reducing the gap between the discovery of MS-based candidate biomarkers and their clinical application.
The protocol described in this chapter has been developed and refined over a period of more than five years, in particular for the analysis of blood serum. It has emerged from extensive tests that have been undertaken in order to establish a high-throughput protocol that provides both precise and accurate measurements. The protocol is based on MALDI-TOF MS profiling of blood samples that are purified employing commercial ZipTip ® technology. As such it is a simple and robust method for providing mass spectral patterns that can be used for sample classification and, thus, potentially for clinical diagnostics and early disease detection.
The overall workflow (see Figure 1 ) is composed of three main steps which are (i) sample collection, (ii) sample preparation and analyte purification, and (iii) MS data acquisition and analysis. It is suitable for both manual and automated sample preparations and analyses 14 .
The automated sample preparation procedures have been developed in our laboratory based on an easy-to-operate and cost-effective robotic platform, a CyBi (ii) Sub-sampling the plasma/serum samples which can be performed either immediately after blood collection at the collection site or later in the MS laboratory. At the end of this step small, ready-to-analyse sample volumes are stored in microtitre plates.
(iii) Purification of analytes (mainly polypeptides) from plasma/serum: This part of the protocol is critical and involves binding the analytes to a chromatographic phase followed by a washing step at which non-bound compounds are removed.
The analytes are then eluted off the chromatographic support before being mixed with the matrix and spotted onto a MALDI target plate. This step is carried out in the MS laboratory (see Figure 2 ).
(iv) MS data acquisition and analysis: This last step consists of collecting MALDI mass spectra under strict QC procedures from the samples prepared above (see Figure 2 ). The obtained data are then analyzed using appropriate software and bioinformatics tools. (including consumables and equipment) might need to be adjusted.
(a) For plasma preparation:
-Centrifuge the blood sample at 13,000 g for 5 min at 4°C.
-Decant the plasma (top layer) to appropriately sized and labelled cryovials, taking care not to disturb the middle whitish layer (mononuclear cells and platelets) or the bottom layer (red blood cells).
(b) For serum preparation:
-Allow blood to clot for 1 h at room temperature keeping the tube in the upright position (see Note 5).
-Spin tubes at 1,400 g for 10 min at room temperature.
-Transfer the serum (upper phase) to appropriately sized and labelled cryovials.
If resources (time, staff and sample storage) allow, as many aliquots of the appropriate volume as possible should be made in order to minimize freezethaw cycles.
3. Immediately store all samples at -80°C.
4. Transport samples to the MS laboratory on dry ice. On arrival they must be immediately stored at -80°C (see Note 6).
Pre-processing and sub-sampling of plasma/serum samples
This protocol assumes that plasma or serum samples will be sub-sampled into microtitre plates before the analyte extraction procedure. The following steps detail this procedure (see Note 7).
1. Remove the sample tubes from the freezer, and allow the samples to thaw on an icebath (see Note 8).
2. Randomize samples before any further steps are taken to avoid any systematic error due to the sample order or history.
3. Transfer the samples from cryostraws to microcentrifuge tubes (this step is only necessary when cryostraws are used such as for long-term, large-scale sample storage):
-Remove the first straw from the freezer and scan the barcode on the straw or, if no bar codes are used, write down the sample details.
-Using scissors, cut the straw just below the closure at the top.
-Invert the straw and place the cut end in a 1.5 mL-tube. Now cut the other end of the straw and dispose of the cut-off pieces in the Virkon ® solution. Wash the scissor blades with ethanol.
-Lift the straw slightly to allow the thawed serum to drain into the tube. Use the pipettor with a tip attached to blow air through the straw from the top down, in order to expel the last few drops of plasma/serum into the tube. Place the empty straw into the Virkon ® solution. Use the pipettor with the same tip still attached to mix the content of the tube, ensuring that the whole sample is thoroughly thawed and homogeneous.
4. Sub-sampling from microcentrifuge tubes to microtitre plates:
-Transfer 5 µL of plasma/serum to the corresponding well in one or more microtitre plates as required, leaving on each microtitre plate 6 wells vacant for the use of control samples as detailed later (see Note 9) . Record the position of each sample on a microtitre plate plan (see Note 10).
-From the remaining volume sub-sample as many aliquots as required into 200 µL-tubes or thermostrips (these can be later used for single point analysis).
-Pipette 5 µL-aliquots of the standard plasma/serum sample (thawed and homogenized) to 3 of the 6 empty wells on the microtitre plates containing samples and record their position on the microtitre plate plans. This standard sample will be used as initial control for the whole run. The 3 remaining empty wells are later used for post-preparation control samples (see SST solution, section 3.3.1).
5. Cover each microtitre plate with a cover lid and secure the lid in place with a rubber band. Put each plate inside a small clear plastic bag, and place the bags together with a copy of the plate plan in a labelled sample box.
6. Immediately freeze the samples and store them at -80°C until required.
Extracting analytes from plasma/serum samples
This protocol describes the manual extraction of mainly polypeptidic analytes from blood plasma/serum which is suitable if the number of samples is just a few. It requires the samples to be in a microtitre plate format suitable for the use of an eight-channel pipettor. However, this protocol can also be applied using single tubes but needs to be adjusted accordingly. For large sample sets and high throughput extraction a liquid handling robot is recommended. TFA. Mix and aliquot at 4 µL. Store the aliquots at -20°C (see Table 1 for a list of PCS components). 
Preparation of solutions (see

Sample clean-up and MALDI sample preparation
1. Preparing the samples -Remove the aliquotted samples from the freezer and thaw them on an Isofreeze PCR rack keeping their temperature at no more than 4°C.
-Immediately after thawing, add 5 µL of 2% TFA to each sample well and aspirate/dispense several times to ensure good mixing.
2. Preparing the ZipTips ® (see Note 13).
-Load 8 ZipTips ® onto a multi-channel pipettor.
-Aspirate 10 µL of ACN onto each ZipTip ® and dispense it to waste. Repeat twice.
-Aspirate 10 µl of 0.1 % TFA onto each ZipTip ® and dispense it to waste. Repeat twice.
3. Binding and washing the analytes -Slowly aspirate and dispense the sample solutions back into the same well. Repeat 9
times.
-Aspirate 10 µL of 0.1 % TFA onto each ZipTip ® and dispense it to waste (or collect if the washing fractions are to be analysed). Repeat twice. 
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-Wait until all MALDI sample spots are completely dry (see Note 14).
MALDI MS data acquisition and analysis
Data acquisition
This protocol describes a typical workflow employing an Ultraflex II MALDI- Table 2 and Note 15). These settings must be optimised for each individual instrument.
2. Insert the MALDI target plate into the mass spectrometer. The plate should be analysed within 2 hours of MALDI sample spotting.
3. Calibrate the mass spectrometer using a single calibrant sample spot containing the PCS mixture (see Note 16). Data should be collected automatically by clicking on the tab "Run method on current spot".
4.
Collect spectra from an SST sample spot to check that shots are accumulated and the AutoXecute evaluation criteria are met (see Note 17 and Figure 2 ). If this is not the case, re-adjust the laser power accordingly and collect spectra from another SST spot to fulfil these conditions. Data should be collected automatically by clicking on the Tab "Run method on current spot". A typical mass spectrum obtained from a pooled human serum sample is shown in Figure 3 .
Load the correct autoXsequence file (containing the names and positions of each
sample on the target as well as the file name and path where the spectra will be saved on the hard disk). This file can be generated by using the spreadsheet from the sample plate plan initially prepared.
6. Start the automatic run by clicking on the tab "Start automatic run". Data collection for a full 384-spot plate (spotted from a full 96-well microtitre plate) takes about 6 hours.
Data quality control and filtering/processing
In the following steps 1,000. By clicking "OK" this will generate a report detailing the spectra with less than 1,000 shots which should then be excluded from further processing.
2. Within the ClinProTools program, load the spectra files of the SST samples by selecting "Open Model Generation Class" under the "File" menu. View the spectra in the pseudo-gel view.
3. Load the spectra of the standard plasma/serum samples, which will be depicted in the pseudo-gel view alongside the spectra of the SST samples. The 2 classes should
give virtually identical spectra, in which case the overall preparation of the batch of samples is deemed acceptable. If the spectra are markedly different or two or more spectra per sample have been excluded further investigation will be needed to determine the cause.
4. Load the spectra of each individual sample as a class into ClinProTools, and inspect them visually to determine any obvious differences within that class. If differences are found it may be necessary to exclude the entire data set for this sample on the basis of poor quality (see Note 18).
Preliminary Data Analysis
Curated spectra sets can be analysed using ClinProTools or exported from 4. When collecting blood samples, a proper phlebotomy technique should be applied.
Ideally, the same amount of blodd is collected for each sample. Haemolysis should be avoided at this step as well as any other (subsequent) steps.
5. Blood should be allowed to clot for exactly 1 hour, otherwise differences in the mass spectral profiles might arise due to different clotting times of the samples.
6. Avoid freeze-thaw cycles at all steps because they induce proteolysis (in the absence of anti-proteases) and the precipitation of peptides/proteins.
7. All sub-sampling must be carried out in an adequate safety cabinet. Equipment and consumables used for the purpose of sub-sampling should be housed inside the cabinet and should be labelled with biohazard labels (tubes, pipette tips, solutions, etc.). Before starting work, ensure that there are two 1-litre Virkon ® solutions available that are less than one week old and still pink. One of the solutions should be placed in a wide-mouthed screw cap jar for disposal of plastic consumables, and the other should be in a screw cap bottle for dealing with accidental spills. 11. The matrix solution should be freshly prepared on the day of the experiment. The solutions of 2% TFA, 0.1% TFA and 50% ACN/0.1% TFA should be replaced weekly.
12. SST solutions/samples are used as controls to check both the performance of the mass spectrometer and the quality of the MALDI sample preparation.
13. Ensure that ZipTips ® do not dry out or aspirate air during the entire procedure.
14. Ensure that the relative humidity in the lab is between 35-60% during MALDI sample preparation (incl. crystallisation). Very low or very high humidity dramatically affects the crystallization and thus, the MALDI MS ion signal.
15. Data acquisition should be automated. In this protocol, an automated workflow is provided for an Ultraflex II TOF/TOF instrument using the instrument's 'AutoXecute' function. Each spectrum is the sum of 1,000 single laser shots randomized over 10 positions within the same spot (100 shots/position) at a laser frequency of 25 Hz. Before each acquisition cycle of 100 laser shots, the new position on the target spot is pre-irradiated with 10 laser shots at 10% higher laser power to improve spectral quality. Evaluation parameters are set so that only spectra (of 100 shots) containing at least one peak with a resolving power of greater than 300 21 and a signal-to-noise ratio of more than 10 in the m/z range of 700-10,000 are accumulated.
16. The calibration can be checked on a second PCS spot and repeated if necessary.
17. Prior to analyzing an entire MALDI target, an SST sample spot should be used for adjusting the laser power and as a general system check. Using this control sample, the resolution and intensity of five major peaks across the mass range 1,800 to 8, 200 Da are typically checked against previously obtained data. If necessary, the laser energy is adjusted to keep the intensity and resolution of these peaks within a range of ± 2 standard deviations. In addition, the overall performance of the mass spectrometer should be thoroughly checked every 2-3 weeks using peptide standards.
18. If the number of replicate spectra per sample falls below 3 as a result of spectra exclusion, it may be necessary to repeat the sample preparation, if this is possible. 
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